Asian Stocks Slide as Semiconductor Selloff Weighs on South Korea and Japan 
Asian Stocks Cautious Ahead of US Jobs Data as Oil Rises 
China Inflation Cools in July as CPI Misses Forecast, PPI Deflation Eases 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
US Job Growth Seen Picking Up in July 
Japan Posts First Current Account Deficit in 17 Months as Dividend Payments Surge 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
US Stock Futures Flat as Iran Strait of Hormuz Demands Fuel Oil Concerns 
US Dollar Near Two-Month Low as Markets Await Inflation Data 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Gold Prices Steady as Hormuz Tensions Fuel Fed Rate Concerns 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Samsung Biologics and Samsung C&T Corp. are investing in Senda Biosciences, a US-based biotechnology company. The two Samsung subsidiaries are set to spend $15 million on the project.
As per The Korea Times, Samsung Biologics and Samsung C&T have set up an investment fund for Senda Biosciences as part of their efforts to strengthen the core technology needed to develop and produce next-generation biopharmaceutical products.
The investment was announced on Wednesday, Aug. 17. The South Korean biotech firm said that it has jointly created the Life Science Fund with the construction and engineering company. They have made the decision to invest in the said American biotech firm after noting it has secured a first-rate programmable drug delivery platform.
Aside from Samsung Life Science Fund, Qatar Investment Authority, Stage 1Ventures, and Bluwave Capital have also invested in the company's Series C financing. Others that have participated in the financing are existing investors such as the State of Michigan Retirement System, Mayo Clinic, Alexandria Venture Investments, Partners Investment, and Longevity Vision Fund. Senda Biosciences raised a total of $266 million in funds as of the moment.
"Senda is pioneering the development of comprehensively programmable medicines with the potential to reach previously inaccessible cells, tissues, and organs," Senda Biosciences' chief executive officer and partner at Flagship Pioneering, Guillaume Pfefer, Ph.D., said in a press release.
He added, "We believe our approach could transform the lives of patients in need of novel treatments, and so we're delighted to have attracted support from investors who recognize this potential and its significance."
Senda Biosciences also operates a platform technology that utilizes artificial intelligence (AI) and machine learning technologies to nanoparticle big data in animals, plants, and bacteria to make an advanced drug delivery system. It is also developing new therapeutic drugs and mRNA vaccines.
Finally, Samsung Biologics has plans to build up its partnership with Senda Biologics once the development of new drugs through the latlatter'schnology commences. Senda was established by Flagship Pioneering which is also known as the founder of Moderna vaccine manufacturer.
